CAC
CTOR

Cowen and Company’s Citius Oncology CTOR Stock Holding History

Cowen and Company’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-627,176
Closed -$7.12M – 700
2024
Q2 		$7.12M Buy
627,176
+112,667
+22% +$1.26M 0.2% 46
2024
Q1 		$5.69M Buy
514,509
+443,432
+624% +$4.88M 0.22% 46
2023
Q4 		$778K Buy
71,077
+42,814
+151% +$466K 0.05% 169
2023
Q3 		$304K Buy
+28,263
New +$302K 0.02% 197

Other funds holding CTOR

YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cowen and Company's CTOR Position: Q3 2024 in Review

Cowen and Company sold out of Citius Oncology (CTOR) in Q3 2024, closing a stake of 627,176 shares — an estimated $7.12M sold.

Cowen and Company first reported a position in CTOR in Q3 2023 and held it in 4 quarters. The position peaked at $7.12M in Q2 2024. 7 funds tracked by Wall St. Rank hold CTOR as of Q3 2024.

  • Cowen and Company reported no remaining Citius Oncology position as of Q3 2024 after selling out during the quarter.
  • Cowen and Company sold 627,176 Citius Oncology shares in Q3 2024, an estimated $7.12M.
  • Cowen and Company first reported a position in Citius Oncology in Q3 2023 and held it in 4 quarters.
  • Cowen and Company's Citius Oncology position peaked at $7.12M in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.